Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe
| Autor: | Rossella Elisei, Enrique Grande, Michael C. Kreissl, Sophie Leboulleux, Tarun Puri, Nicolas Fasnacht, Jaume Capdevila |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Elisei R] Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. [Grande E] Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain. [Kreissl MC] Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital of Magdeburg, Magdeburg, Germany. [Leboulleux S] Department of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Geneva University Hospitals, Geneva, Switzerland. [Puri T, Fasnacht N] Medical Affairs, Eli Lilly and Company, Indianapolis, IN, United States. [Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOBTeknon, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: |
Cancer Research
Oncology acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS] Otros calificadores::/uso terapéutico [Otros calificadores] Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Tiroide - Càncer - Tractament Other subheadings::/therapeutic use [Other subheadings] Other subheadings::Other subheadings::/drug therapy [Other subheadings] Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms [DISEASES] Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS] Proteïnes quinases - Inhibidors - Ús terapèutic neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides [ENFERMEDADES] |
| Zdroj: | Scientia |
| Popis: | Medullary thyroid cancer; Tyrosine kinase inhibitor Cáncer medular de tiroides; Inhibidor de la tirosina cinasa Càncer medul·lar de tiroide; Inhibidor de la tirosina cinasa The incidence of thyroid cancer is increasing worldwide with the disease burden in Europe second only to that in Asia. In the last several decades, molecular pathways central to the pathogenesis of thyroid cancer have revealed a spectrum of targetable kinases/kinase receptors and oncogenic drivers characteristic of each histologic subtype, such as differentiated thyroid cancer, including papillary, follicular, and medullary thyroid cancer. Oncogenic alterations identified include B-Raf proto-oncogene (BRAF) fusions and mutations, neurotrophic tyrosine receptor kinase (NTRK) gene fusions, and rearranged during transfection (RET) receptor tyrosine kinase fusion and mutations. Multikinase inhibitors (MKIs) targeting RET in addition to multiple other kinases, such as sorafenib, lenvatinib and cabozantinib, have shown favourable activity in advanced radioiodine-refractory differentiated thyroid cancer or RET-altered medullary thyroid cancer; however, the clinical utility of MKI RET inhibition is limited by off-target toxicity resulting in high rates of dose reduction and drug discontinuation. Newer and selective RET inhibitors, selpercatinib and pralsetinib, have demonstrated potent efficacy and favourable toxicity profiles in clinical trials in the treatment of RET-driven advanced thyroid cancer and are now a therapeutic option in some clinical settings. Importantly, the optimal benefits of available specific targeted treatments for advanced RET-driven thyroid cancer require genetic testing. Prior to the initiation of systemic therapy, and in treatment-naïve patients, RET inhibitors may be offered as first-line therapy if a RET alteration is found, supported by a multidisciplinary team approach. This manuscript was funded by Eli Lilly and Company. The funder reviewed the manuscript and was involved in the decision to submit it for publication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|